Hansoh Pharma's Forxiga Included in National Diabetes Guidelines, Boosting GLP-1 Drug Global Expansion

Introduction

Hansoh Pharma's self-developed GLP-1RA weekly formulation 'Forxiga®' has been officially included in the 'Clinical Guidelines for Prevention and Treatment of Type 2 Diabetes in the Elderly in China (2026 Edition)'. As these guidelines serve as a core reference for NMPA reviews and医保 negotiations, this authoritative endorsement is expected to accelerate the registration process for similar Chinese innovative drugs in emerging markets such as Southeast Asia, Latin America, and the Middle East. The development is particularly significant for CDMO companies with dual GMP certifications (China + NMPA-recognized countries) aiming to secure overseas localization production orders.

Event Overview

The inclusion of Hansoh Pharma's Forxiga® in the national diabetes guidelines marks a pivotal step for the company and the broader GLP-1 drug market. The guidelines, which are a key benchmark for regulatory and reimbursement decisions, provide a strong foundation for the drug's domestic and international expansion. While the exact timeline of the event is not specified, the move is expected to have immediate implications for the pharmaceutical and CDMO sectors.

Impact on Sub-sectors

Pharmaceutical Manufacturers

The inclusion of Forxiga® in the guidelines underscores the growing acceptance of Chinese-developed GLP-1 drugs. Manufacturers with similar products in the pipeline may benefit from streamlined regulatory pathways in emerging markets.

CDMO Companies

CDMO firms with dual GMP certifications are poised to gain from increased demand for localized production in target markets. The guidelines' endorsement enhances the credibility of Chinese-manufactured drugs, making it easier for these companies to secure contracts.

Regulatory and Compliance Services

With the clearer合规 path for GLP-1 drugs, regulatory and compliance service providers may see a surge in demand from pharmaceutical companies seeking to navigate the approval processes in emerging markets.

Key Focus Areas and Recommendations

Monitor Regulatory Updates

Companies should closely follow any subsequent updates to the guidelines or related policies to stay ahead of regulatory changes.

Prioritize Emerging Markets

Given the指南's potential to facilitate market entry, businesses should prioritize Southeast Asia, Latin America, and the Middle East for expansion.

Strengthen Local Partnerships

Building strong relationships with local partners in target markets can help mitigate risks and accelerate market penetration.

Editor's Perspective

From an industry standpoint, this development is more than just a milestone for Hansoh Pharma; it signals a broader shift in the global pharmaceutical landscape. The指南's endorsement serves as a catalyst for Chinese创新 drugs, particularly in markets where regulatory hurdles have traditionally been high. However, it's crucial to view this as a starting point rather than a definitive outcome, as the actual impact will depend on how effectively companies leverage this opportunity.

Conclusion

The inclusion of Forxiga® in the national diabetes guidelines is a significant step forward for the Chinese pharmaceutical industry. It not only validates the quality of domestically developed GLP-1 drugs but also opens up new avenues for global expansion. For now, the industry should interpret this as a positive signal and prepare to capitalize on the emerging opportunities in targeted markets.

Source Information

Primary Source: 'Clinical Guidelines for Prevention and Treatment of Type 2 Diabetes in the Elderly in China (2026 Edition)'
Note: The exact timeline of the event and further details on market-specific impacts remain to be observed.